Venus Remedies
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Venus Remedies is poised for stable growth, driven by management's disciplined focus on operational efficiency and digital transformation. Recent commentary highlights a strategic shift towards enhancing R&D capabilities, particularly in critical care and antimicrobial resistance, which aligns with the company's long-term growth objectives. The emphasis on 'Right At First Time' quality standards is expected to bolster competitive positioning and margins. Vista's financial outlook reflects a stable revenue trajectory, with margins anticipated to remain consistent, supported by a favorable regulatory environment and a strong pipeline of innovative products. However, the company must navigate rising input costs and pricing pressures in the US market, which could impact profitability. Over the next 12-24 months, key opportunities include expanding into high-growth international markets and leveraging digital tools for operational efficiency. Conversely, watchpoints include potential regulatory challenges and volatility in domestic market expansion due to M&A activities. Overall, the investment outlook remains positive, with an expected upside of approximately 30.7% and a target price of ₹2092.11
Why We Like This Stock
- Management's focus on digital transformation and operational efficiency is expected to enhance margins and competitive positioning
- A strong R&D pipeline in critical care and antimicrobial resistance aligns with market demand and long-term growth strategies
- Favorable regulatory conditions and a diversified global presence provide a buffer against typical industry risks
Things To Watch Out For
- Rising input costs may pressure profit margins across the sector
- Pricing challenges in the US market could impact overall profitability
- Potential regulatory scrutiny and volatility in domestic market expansion pose risks to growth
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 596 | 640 | 770 | 891 | 1,032 |
| Profit Before Tax (Cr.) | 44 | 60 | 134 | 160 | 184 |
| PBT Margin | 7.5% | 9.4% | 17.4% | 17.9% | 17.8% |
| Net Profit (Cr.) | 32 | 44 | 101 | 121 | 139 |
| Earnings Per Share | 24.2 | 33.2 | 75.4 | 90.0 | 103.6 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management. It also provides analgesic, analgesic and antipyretic, antibiotic, antidiabetic anticoagulant, antiemetic, antiviral, cardiac, cardiovascular, CNS, disinfectant and antiseptic, gastro therapy, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, mucolytic, muscle relaxant, neurology, respiratory, stress reliver, urology, vitamins, nutrients, minerals, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.